The Risk of Myocardial Infarction Associated with Inhaled β -Adrenoceptor Agonists
Authors:
- 1 March 2000
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 161 (3) , 827-830
Abstract
Beta-adrenoceptor agonists ( β -agonists), in widespread clinical use for obstructive lung disease, have been associated with an increased risk of cardiovascular mortality. The objective of this study was to assess the association between incident myocardial infarction and the use of inhaled β -agonists. We performed a case-control study within the Group Health Cooperative of Puget Sound (GHC). Between 1989 and 1994, we identified 1,444 cases with an incident myocardial infarction and 4,094 control subjects frequency-matched on age, sex, hypertension, and index date. The computerized pharmacy database of the health maintenance organization (HMO) was used to assess the use of β -agonists by metered dose inhaler (MDI). Cardiovascular risk factor information was obtained from medical record review. In comparison to subjects who did not fill a β -agonist prescription, subjects who had filled one β -agonist MDI prescription in the 3 mo prior to their index date had an elevated estimated risk of myocardial infarction (adjusted odds ratio [OR]: 1.67 [95% CI, 1.07 to 2.60]). The elevated risk was limited to those subjects who had a history of cardiovascular disease (adjusted OR: 3.22 [95% CI, 1.63 to 6.35]) and among those with cardiovascular disease, to new users of β -agonists (adjusted OR: 7.32 [95% CI, 2.34 to 22.8]). There was no dose–response relationship between β -agonists use and risk of myocardial infarction. In this study, new use of β -agonists was associated with an increased risk of myocardial infarction, although we cannot determine if the association is causal. Our study suggests that clinicians should exercise caution when giving an initial β -adrenoceptor agonist prescription to patients with cardiovascular disease. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM. The risk of myocardial infarction associated with inhaled β -adrenoceptor agonists.Keywords
This publication has 22 references indexed in Scilit:
- Effect of short- and long-acting β2-adrenoceptor agonists on pulmonary β2-adrenoceptor expression in human lungEuropean Journal of Pharmacology, 1996
- Differential down-regulation of pulmonary β1- and β2-adrenoceptor messenger RNA with prolonged in vivo infusion of isoprenalineEuropean Journal of Pharmacology: Molecular Pharmacology, 1993
- The Use of β-Agonists and the Risk of Death and near Death from AsthmaNew England Journal of Medicine, 1992
- Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study.Thorax, 1991
- Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthmaThe Lancet, 1990
- Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81.Thorax, 1990
- PRESCRIBED FENOTEROL AND DEATH FROM ASTHMA IN NEW ZEALAND, 1981-83; CASE-CONTROL STUDYThe Lancet, 1989
- Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial InfarctionNew England Journal of Medicine, 1981
- Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration.Journal of Clinical Investigation, 1980
- Elevated beta-adrenergic receptor number after chronic propranolol treatmentBiochemical and Biophysical Research Communications, 1977